71825-33-7

Upstream product

• 100-14-1 4-nitrobenzyl chloride 
• 22978-64-9 4-(4-nitro-phenyl)-butyronitrile 
• 1146975-07-6 4-[4-(t-Butoxycarbonylamino)phenyl]butanenitrile 
• 61445-60-1 4-(4-nitro-phenyl)-butyric acid amide 
• 20637-02-9 methyl 4-(4-nitrophenyl)butanoate 
• 61081-32-1 1-nitro-4-(4-tolylsulfonylmethyl)benzene 
• 77853-44-2 4-(4-Nitro-phenyl)-4-(toluene-4-sulfonyl)-butyronitrile 

Downstream Products

• 117293-78-4 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluoro-N-[4-(3-cyanopropyl)phenyl]octanamide 
• 117293-69-3 2,2,3,3,4,4,4-Heptafluoro-N-{4-[3-(1H-tetrazol-5-yl)-propyl]-phenyl}-butyramide 
• 117293-68-2 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluoro-octanoic acid {4-[3-(1H-tetrazol-5-yl)-propyl]-phenyl}-amide 
• 1146975-11-2 4-(4-((2-cyanopropan-2-yl)amino)phenyl)butanenitrile 
• 1146975-13-4 4-[4-(1-Cyanocyclopentyl amino)phenyl]butanenitrile 

Relevant academic research and scientific papers

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis.

DIARYLHYDANTOIN COMPOUNDS

The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

N-(1H-tetrazol-5-yl-alkylphenyl)polyfluoroalkanamides

Compounds of the formula: STR1 where R is hydrogen or A--(CF2)m --CH2 --; A is --F or --H; n is an integer from 1 to 10, inclusive; m is an integer from 0 to 9, inclusive; p is an integer from 0 to 4, inclusive; and Y is h